

This is a paid press release. Contact the press release distributor directly with any inquiries.

CISION

## The HKIC Presents Stellar Annual Report and Joins Hands with Beyond Ventures to Support World-Class Ophthalmic Healthcare Flagship Projects

PR Newswire

Fri, July 17, 2026 at 9:14 AM GMT+8 • 5 min read



*"Patient Capital" Nurtures Life Science Innovations: MingMed and Super Vision Featured as Selected Investment Stories in the HKIC's Annual Report*

HONG KONG, July 17, 2026 /PRNewswire/ -- **Beyond Ventures**, a Hong Kong-based venture capital firm, warmly congratulates the Hong Kong Investment Corporation Limited (HKIC) on the release of its highly encouraging 2025 Annual Report. The report reveals that in 2025, the HKIC recorded a total of investment income of over HK\$6.4 billion while its cumulative projects expanded to more than 200 as of the end of June 2026. In the annual report, two outstanding life science enterprises co-invested by Beyond Ventures and the HKIC – MingMed and Super Vision were honored as featured investment stories. This is not only a high recognition of both companies, but also a powerful demonstration of the HKIC's investment philosophy and Hong Kong's unique role as a "Super Connector" and "Super Value-Adder."

### **Significant Commercial Value Embedded with Deep Social Impact** **Mr. Lap Man, Co-Founder and Managing Partner of Beyond**

**Ventures**, remarked: "The i-NYS implantable eye muscle-nerve stimulation device, independently developed by Super Vision, is the world's first Class III active implantable medical device targeting congenital nystagmus. This 'world-first' breakthrough brings real hope to over 7 million patients worldwide who suffer from this rare disease. What's more, 'Brain-Computer Interface' (BCI) has been officially written into the National 15th Five-Year Plan as one of the National future strategic industries. Super Vision has already initiated projects for its visual brain-computer interface (NeuraVision), moving toward the ultimate goal of restoring functional sight to visually impaired patients and further filling a gap in global medical technology."

Mr. Lap Man added: "Meanwhile, MingMed has also achieved milestone progress in the field of oral drug therapies. In May this year, at the annual meeting of the prestigious Association for Research in Vision and Ophthalmology (ARVO), MingMed was among the few invited to present in a dedicated session its Phase II clinical trial data for its first-in-class oral drug QA102 for the treatment of intermediate to advanced dry Age-related Macular Degeneration (Dry AMD), the world's third leading cause of blindness. Coupled with an overall favorable safety and tolerability profile, this has drawn high attention from both academia and renowned pharmaceutical companies, laying a solid foundation for subsequent Phase III clinical design and dosage optimization, as well as potential out-licensing/collaboration opportunities. It is expected to bring new hope to tens of millions of patients worldwide at risk of blindness in the future."

These two major projects not only possess substantial commercial potential but also effectively address unmet global clinical needs, creating irreplaceable social and livelihood benefits.

### **Professional Operation of Patient Capital: Delivering Value Beyond Capital**

Biotechnology is a long-cycle industry requiring high R&D investment - a marathon that tests endurance and expertise, requiring the backing of long-term patient capital. The continuous delivery of technological and clinical breakthroughs by these two enterprises' post-investment validates the strategic resolve and profound industry insights of the investment teams at Beyond Ventures and the HKIC as "patient capital."

With the assistance of Beyond Ventures and the HKIC, Super Vision is actively preparing for product registration and distribution in Hong Kong, using Hong Kong as a springboard to advance US clinical trials. It obtained Humanitarian Use Device (HUD) designation from the US Food and Drug Administration (FDA) last year while MingMed has also kick-started collaborations with biotech projects at multiple universities in Hong Kong. This demonstrates that Beyond Ventures and the HKIC have gone beyond simple capital injection; they are simultaneously focusing on promoting the deep integration of Hong Kong's innovation and technology (I&T) ecosystem with high-quality mainland enterprises, helping them take root in Hong Kong, and clinical breakthroughs by these two enterprises' post-investment validates the strategic resolve and profound industry insights of the investment teams at Beyond Ventures and the HKIC as "patient capital."

With the assistance of Beyond Ventures and the HKIC, Super Vision is actively preparing for product registration and distribution in Hong Kong, using Hong Kong as a springboard to advance US clinical trials. It obtained Humanitarian Use Device (HUD) designation from the US Food and Drug Administration (FDA) last year while MingMed has also kick-started collaborations with biotech projects at multiple universities in Hong Kong. This demonstrates that Beyond Ventures and the HKIC have gone beyond simple capital injection; they are simultaneously focusing on promoting the deep integration of Hong Kong's innovation and technology (I&T) ecosystem with high-quality mainland enterprises, helping them take root in Hong Kong, and leveraging Hong Kong's international advantages to enter the global market, thereby opening a two-way channel between premier mainland tech enterprises and Hong Kong's I&T ecosystem.

### **The Power of Professional Patient Capital Will Continue to Release Value, Benefiting the World with Innovation Achievements**

Super Vision and MingMed are just two of the investment stories among the numerous co-investment projects of Beyond Ventures and the HKIC. Over time, we believe that this capital power, combining patience and professionalism, will continue to manifest, nurturing more great enterprises that not only achieve immense commercial success but also tangibly improve human well-being and generate profound social value globally.

We once again congratulate the HKIC on the highly impressive and fruitful achievements showcased in its 2025 Annual Report! Beyond Ventures looks forward to continuing to walk shoulder-to-shoulder with the HKIC in the future to jointly support and consolidate Hong Kong's position as a global hub for innovation.

### **About Beyond Ventures**

Beyond Ventures, the Hong Kong-based venture capital firm, was co-founded by Lap Man and Marvin Hung in 2017 with the goal to revitalize and transform Hong Kong's innovation ecosystem by being the city's most impactful venture capital firm. The firm unites venture capital experts and local conglomerates with visionary entrepreneurs, providing start-ups with the capital and guidance they need to thrive.

With the assistance of Beyond Ventures and the HKIC, Super Vision is actively preparing for product registration and distribution in Hong Kong, using Hong Kong as a springboard to advance US clinical trials. It obtained Humanitarian Use Device (HUD) designation from the US Food and Drug Administration (FDA) last year while MingMed has also kick-started collaborations with biotech projects at multiple universities in Hong Kong. This demonstrates that Beyond Ventures and the HKIC have gone beyond simple capital injection; they are simultaneously focusing on promoting the deep integration of Hong Kong's innovation and technology (I&T) ecosystem with high-quality mainland enterprises, helping them take root in Hong Kong, and leveraging Hong Kong's international advantages to enter the global market, thereby opening a two-way channel between premier mainland tech enterprises and Hong Kong's I&T ecosystem.

The name "Beyond Ventures" originates from the popular rock-and-roll band Beyond, which emerged in early 1990s Hong Kong. Since raising its first fund in 2017, Beyond Ventures has successfully invested in and helped develop portfolio companies which include SenseTime, Smartsens, YOHO, HKTaxi (acquired by Uber in 2021), G-NiiB, a biotech spinout from the CUHK, Hongene, a global leading supplier of core raw materials for nucleic acid drugs and MingMed, an innovative biotech company specializing in the development of first-in-class drugs, among others. To date, the portfolio has produced four IPOs, three trade sales, and three filings under Chapter 18A or 18C on the Hong Kong Stock Exchange.

Beyond Ventures draws on support from well-known Hong Kong conglomerates including Hop Hing Group, Far East Consortium, Chinney Alliance Group and Chinachem Group, leading private equity firms Hony Capital and GAW Capital, Hong Kong VC firm, eGarden as well as the endowment fund of The University of Hong Kong.

Please visit [www.beyondventures.hk](http://www.beyondventures.hk) for more information.

View original content:<https://www.prnewswire.com/apac/news-releases/the-hkic-presents-stellar-annual-report-and-joins-hands-with-beyond-ventures-to-support-world-class-ophthalmic-healthcare-flagship-projects-302828156.html>



CISION

## 港投公司年度報告交出亮眼成績與海闊天空創投攜手支持世界級眼科醫療標杆項目

PR Newswire Asia

2026年7月17日週五 上午9:12 [GMT+8]



以耐心資本澆灌生命科技之花 - 因明生物及超目科技入選港投公司年度報告中的精選投資故事

香港2026年7月17日 /美通社/ -- 以香港為基地的風險創投公司**海闊天空創投 (Beyond Ventures)** 熱烈恭賀香港投資管理有限公司 (港投公司) 發佈令人鼓舞的2025年年度報告。該報告顯示，回顧2025年，港投公司錄得逾64億港元的投資收入總額，而截至2026年6月底，累計投資及帶動項目超過200個。在年度報告中，由海闊天空創投與港投公司聯合投資的兩家優秀的生命科技企業 - 因明生物(MingMed)和超目科技(Super Vision)雙雙獲選為當中的精選投資故事。這不僅是對兩家企業的高度認可，也充分彰顯了港投公司的投資理念，以及香港作為「超級聯繫人」和「超級增值人」的獨特角色。

**不僅具備顯著的商業價值，更承載著深遠的社會意義**

**海闊天空創投聯合創辦人及管理合夥人文立先生 (Lap Man)**表示：「超目科技自主研發的 i-NYS 植入式眼部肌肉神經刺激器，是全球首款針對先天性眼球震顫的三類有源植入醫療器械。這一「全球首創」的突破，為全球逾700萬深受此困擾的罕見病患者帶來切實希望。更令人期待的是，「腦機介面」被正式寫入國家「十五五」規劃，成為國家未來戰略產業之一，超目科技已啟動視覺腦機介面 (NeuraVision) 項目，向著讓視障患者重見光明的終極目標邁進，進一步填補全球醫療技術空白。」

文立先生補充：「與此同時，因明生物在口服藥物治療領域同樣取得了里程碑式的進展。其針對全球第三大致盲疾病乾性年齡相關性黃斑變性 (Dry AMD) 於今年五月在國際權威國際視覺與眼科學研究協會 (ARVO) 年會上，為少數獲邀通過專題會議形式報告了其全球首創口服新藥QA102治療中晚期乾性AMD的二期臨床研究數據，加上數據安全性與耐受性整體良好，引發學術界及知名藥廠的高度關注，為後續第三期臨床設計與劑量優化以及潛在的對外授權或合作奠定了堅實基礎，有望在未來為全球數以千萬計面臨失明風險的患者帶來新的曙光。」

此兩大項目不但具備可觀的商業化潛力，更能切實解決全球性未滿足的臨床需求，創造不可替代的民生社會效益。

## 耐心資本專業運作，超越資本的價值

生物科技屬於長週期、高研發投入，一場考驗耐力與專業度的長跑，需要長線耐心資本的托底。而這兩家企業投後持續兌現技術與臨床成果，印證海闊天空創投與港投公司作為「耐心資本」的戰略定力以及其投資團隊深厚的行業洞察力。

在海闊天空創投與港投公司的協助下，超目科技正積極籌備在香港進行產品註冊及產品分銷，並以香港為跳板推進美國臨床試驗，去年已獲得美國食品藥品監督管理局(FDA)的人道主義使用器械（HUD）認證。因明生物亦已與香港多所大學的生物科技項目開展合作。由此可見，海闊天空創投與港投公司已超越單純資金注入，他們同時著力促進香港創科生態與內地優質企業的深度融合，協助他們紮根香港，並借助香港國際化優勢走向全球市場，打通內地優質創科企業與香港創科生態圈的雙向通道。

## 專業耐心資本力量將持續釋放價值，讓創新成果惠及全球

超目科技與因明生物，僅僅是海闊天空創投與港投公司眾多聯合投資項目中的投資案例。隨著時間推移，我們相信這種兼具耐心與專業的資本力量將持續顯現，孕育出更多不僅在商業上取得巨大成功，更能切實改善人類福祉、為全球產生深遠社會價值的偉大企業。

我們再次祝賀港投公司 2025年年度報告中取得令人驚喜的豐碩成果！海闊天空創投期待在未來繼續與港投公司並肩同行，共同支持並鞏固香港作為全球創新樞紐的地位。

## 關於 海闊天空創投

海闊天空創投是一家以香港為基地的風險創投公司，由文立及洪明基於2017年共同創立，旨在重塑及轉化香港的創新生態圈，成為本地最具影響力的創投公司。該公司匯聚創投專家、本地大型企業與具遠見的創業者，為初創企業提供所需資金及指導。

「海闊天空創投」的名稱源自1990年代初在香港崛起的搖滾樂隊

「Beyond」。自2017年成立首支基金以來，海闊天空創投成功投資並協助發展的企業包括：商湯科技、思特威、YOHO、HKTaxi（2021年被 Uber 收購）、G-NiiB（源自香港中文大學的生物科技公司）、兆維科技（全球領先的核酸藥物原料供應商）及因明生物（專注於開發首創藥物的創新生物科技公司）等。迄今為止，被投企業已產出四家上市公司、三家企業被收購，同時有三家被投企業已在港交所提交了第18A章或第18C章的上市申請。

海闊天空創投獲得合興集團、遠東發展、建聯集團、華懋集團等香港知名商業集團，領先的私募投資管理公司弘毅投資、基匯資本，本地創投公司eGarden以及香港大學捐贈基金等支持。

請瀏覽[www.beyondventures.hk](http://www.beyondventures.hk)了解更多海闊天空創投的資訊。

C

Cision

View original content:<https://www.prnewswire.com/apac/zh/news-releases/-302828154.html>